1 / 8

Blood Cancer Drugs Market Worth $55.6 Billion by 2025 | CAGR: 11.1%

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period.

priyankauke2013
Download Presentation

Blood Cancer Drugs Market Worth $55.6 Billion by 2025 | CAGR: 11.1%

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Blood Cancer Drugs Market Market Set to Exceed $55.6 Billion by 2025 | CAGR: 11.1%

  2. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 “Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T- Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025” The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period. The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma. Browse Detailed Research Report On Blood Cancer Drugs Market: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety - 2 -

  3. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world. Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region. The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others. Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The - 3 -

  4. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China. Request for sample:https://www.polarismarketresearch.com/industry-analysis/global-blood- cancer-drugs-market/request-for-sample Table of Contents 1. Overview and Scope 1.1. Research goal & scope 1.2. Research assumptions 1.3. Research methodology 1.3.1. Primary data sources 1.3.2. Secondary data sources 1.4. Key take-away 1.5. Stakeholders 2. Executive Summary 2.1. Market definition 2.2. Market segmentation 3. Blood cancer drugs market Insights 3.1. Blood Cancer Drug – Industry snapshot 3.1.1. Leading Companies 3.1.2. Emerging Companies & Technologies Platform 3.1.3. Key Companies to Watch 3.2. Blood Cancer Drug - Ecosystem analysis 3.2.1. Disease overview 3.2.2. Commercial Landscape 3.2.3. Future Treatment Paradigm 3.3. Blood cancer drugs market Dynamics 3.3.1. Blood Cancer Drug – Market Forces 3.3.1.1. Blood cancer drugs market Driver Analysis 3.3.1.2. Blood cancer drugs market Restraint/Challenges analysis 3.3.1.3. Blood Cancer Market Opportunity Analysis 3.3.2. Industry analysis - Porter's five forces 3.3.2.1. Bargaining power of supplier 3.3.2.2. Bargaining power of buyer 3.3.2.3. Threat of substitute 3.3.2.4. Threat of new entrant 3.3.2.5. Degree of competition 3.3.3. Blood cancer drugs market PEST Analysis, 2017 3.3.4. Blood cancer drugs market Value Chain Analysis 3.3.5. Blood Cancer Drug Industry Trends 3.3.6. Competitive Ranking Analysis 4. Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type 4.1. Key Findings 4.2. Lymphoma 4.2.1. Hodgkin Lymphoma - 4 -

  5. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 4.2.2. Non-Hodgkin Lymphoma 4.2.2.1. B-cell Lymphoma 4.2.2.1.1. 4.2.2.1.2. 4.2.2.1.3. 4.2.2.1.4. 4.2.2.2. T-cell Lymphoma 4.2.2.2.1. 4.2.2.2.2. 4.2.3. Leukemia 4.2.3.1. Acute Myeloid Leukemia 4.2.3.2. Chronic Myeloid Leukemia 4.2.3.3. Acute Lymphoblastic Leukemia 4.2.3.4. Chronic Lymphocytic Leukemia 4.2.4. Myeloma 4.2.4.1. Multiple Myeloma 5. Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs 5.1. Rituaxan/Mabthera (Rituximab) 5.2. Gleevac/Glivec (Imatinib) 5.3. Revlimid (Lenalidomide) 5.4. Velcade (Bortezomib) 5.5. Tasigna (Nilotinib) 5.6. Pomalyst (Pomalidomide) 5.7. Vidaza (Azacitidine) 5.8. Kyprolis (Carfilzomib) 5.9. Adcetris (Brentuximab Vedotin) 5.10. Others 6. Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches 6.1. Key Findings 6.2. Chemotherapeutic 6.3. mAbs/Targeted Therapies 6.4. Immunotherapeutic 7. Blood cancer drugs market Size and Forecast, 2017-2025 by Region 7.1. Key Findings 7.2. North America 7.2.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.2.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.2.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.2.4. U.S. 7.2.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.2.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.2.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.2.5. Canada 7.2.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.2.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.2.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.3. Europe 7.3.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.3.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.3.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.3.4. UK 7.3.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 Diffuse Large B-Cell Lymphoma Mantle Cell Lymphoma Burkitt Lymphoma Central Nervous System Lymphoma Precursor T-Lymphoblastic Lymphoma Peripheral T-Lymphoma - 5 -

  6. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 7.3.4.2. 7.3.4.3. 7.3.5. Germany 7.3.5.1. 7.3.5.2. 7.3.5.3. 7.3.6. France 7.3.6.1. 7.3.6.2. 7.3.6.3. 7.4. Asia-Pacific 7.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.4. China 7.4.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.5. Japan 7.4.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.6. India 7.4.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.5. Latin America 7.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.5.4. Brazil 7.5.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.5.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.5.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.5.5. Mexico 7.5.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.5.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.5.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.6. Middle East & Africa 7.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 8. Company Profiles 8.1. Johnson & Johnson Inc. 8.1.1. Overview 8.1.2. Financials 8.1.3. Product Benchmarking 8.1.4. Recent Developments 8.2. Amgen Inc. 8.2.1. Overview 8.2.2. Financials 8.2.3. Product Benchmarking Blood Cancer Drugs Market by drugs, 2017 – 2025 Blood Cancer Drugs Market by treatment approach, 2017 – 2025 Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 Blood Cancer Drugs Market by drugs, 2017 – 2025 Blood Cancer Drugs Market by treatment approach, 2017 – 2025 Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 Blood Cancer Drugs Market by drugs, 2017 – 2025 Blood Cancer Drugs Market by treatment approach, 2017 – 2025 - 6 -

  7. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 8.2.4. Recent Developments 8.3. Bayer AG. 8.3.1. Overview 8.3.2. Financials 8.3.3. Product Benchmarking 8.3.4. Recent Developments 8.4. Pfizer Inc. 8.4.1. Overview 8.4.2. Financials 8.4.3. Product Benchmarking 8.4.4. Recent Developments 8.5. Eli Lily & Co. 8.5.1. Overview 8.5.2. Financials 8.5.3. Product Benchmarking 8.5.4. Recent Developments 8.6. AstraZeneca 8.6.1. Overview 8.6.2. Financials 8.6.3. Product Benchmarking 8.6.4. Recent Developments 8.7. AbbVie Inc. 8.7.1. Overview 8.7.2. Financials 8.7.3. Product Benchmarking 8.7.4. Recent Developments 8.8. Roche Holding AG 8.8.1. Overview 8.8.2. Financials 8.8.3. Product Benchmarking 8.8.4. Recent Developments 8.9. Celgene Corporation. 8.9.1. Overview 8.9.2. Financials 8.9.3. Product Benchmarking 8.9.4. Recent Developments 8.10. Merck and Company 8.10.1. Overview 8.10.2. Financials 8.10.3. Product Benchmarking 8.10.4. Recent Developments 8.11. Novartis AG. 8.11.1. Overview 8.11.2. Financials 8.11.3. Product Benchmarking 8.11.4. Recent Developments 8.12. GlaxoSmithKline Pharmaceuticals Ltd. 8.12.1. Overview 8.12.2. Financials 8.12.3. Product Benchmarking 8.12.4. Recent Developments - 7 -

  8. Blood Cancer Drugs Market Size to Reach $55.6 Billion by 2025 Access Press Release on Blood Cancer Drugs Market: https://www.polarismarketresearch.com/press-releases/global-blood-cancer-drugs-market About Polaris Market Research Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. E mail Id: sales@polarismarketresearch.com Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com - 8 -

More Related